SCHEMBL15344992

SCHEMBL15344992

Cc1ccnc(N2CC3CCCCN3C2=O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.50
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
CCR1 P32246 1/20 0.38
CCR5 P51681 1/20 0.38
CCR8 P51685 1/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
CPT2 P23786 1/20 0.37
CPT1A P50416 1/20 0.37
CPT1B Q92523 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15341947 0.84 GRM5 (0.50) GRM5
SCHEMBL3782058 0.75 CCR1 (0.52) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL2523558 0.72 GRM5 (0.63) GRM5L3MBTL1PIK3CA
SCHEMBL17033299 0.71 CCR1 (0.43) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL11983520 0.70 CCR1 (0.46) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
SCHEMBL10275026 0.70 CCR1 (0.50) CYP3A4CYP2C9CYP2C19ALDH1A1L3MBTL1
SCHEMBL12234478 0.69 GRM5 (0.71) GRM5CYP3A4ALDH1A1KDM4ECCR5
SCHEMBL12235335 0.69 GRM5 (0.69) GRM5CDK5CDK5R1CCR5PIK3CA
SCHEMBL7845856 0.69 CCR1 (0.44) CYP3A4CYP2C9CYP2C19ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL5616058 0.69 HRH3 (0.45) CCR1CCR5CCR8CPT2CPT1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 GRM5 2594/4885CYP3A4 272/4885CYP2C9 617/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 GRM5 2594/4885CYP3A4 272/4885CYP2C9 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.